natgillin/translations-raw huggingface dataset:
The method according to claim 1, wherein the crosslinked hyaluronic acid of step a) is previously obtained from the crosslinking of a non-crosslinked hyaluronic acid with an effective amount of at least one crosslinking agent selected from the group consisting of 1,4-butanediol diglycidyl ether (BDDE), 1,4-bis(2,3-epoxypropoxy)butane, 1,4-bisglycidyloxybutane, 1,2-bis(2,3-epoxypropoxy)ethylene, 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane, pustrescine, spermidine, spermine, and a mixture thereof. 
Postupak prema patentnom zahtjevu 1, naznačen time što se umrežena hijaluronska kiselina iz koraka a) prethodno dobiva iz umrežavanja ne-umrežene hijaluronske kiseline s učinkovitom količinom najmanje jednog sredstva za umrežavanje koje se bira iz skupine koja sadrži 1,4-butandiol diglicidil eter (BDDE), 1,4-bis(2,3-epoksipropoksi)butan, 1,4-bisglicidiloksibutan, 1,2-bis(2,3-epoksipropoksi)etilen, 1-(2,3-epoksipropil)-2,3-epoksicikloheksan, pustrescin, spermidin, spermin, te njihovu smjesu.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 1, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof. 
Farmaceutska kompozicija, koja sadrži farmaceutski prihvatljiv nosač i spoj iz bilo kojeg od patentnih zahtjeva 1-21, ili njegov stereoizomer, tautomer, ili farmaceutski prihvatljivu sol.
is selected from the group consisting of phenyl, Het and Hetaryl; 
je odabran iz skupine koja se sastoji od metila i etila;
The compound of formula 1b or of formula 1b' according to claim 1, wherein R1 is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, thiophenyl, furanyl, pyrazolopyridinyl, indazolyl, thiazolyl, imidazo-pyridinyl and indolyl, wherein this R1 -residue is attached to the rest of the molecule either via a C-atom or via an N-atom and is optionally further substituted by one, two or three substituents Z, whereby each Z is a substituent selected from the group consisting of 
Spoj formule 1c ili formule 1c’ prema patentnom zahtjevu 17, naznačen time, da je odabran iz skupine koja se sastoji od piridinila, pirimidinila, pirazinila, pirolila, imidazolila, pirazolila, tiofenila, furanila, pirazolopiridinila, indazolila, tiazolila, imidazo-piridinila i indolila, gdje je taj R1 –ostatak priključen na preostali dio molekule bilo putem C-atoma ili putem N-atoma i opcionalno je dalje supstituiran s jednim, dva ili tri supstituenta Z, pri čemu je svaki Z supstituent odabran iz skupine koja se sastoji od sljedećih:
OH, oxo, -CN, halogen, methyl, ethyl, n-propyl, isopropyl, -C1-6-haloalkyl, three- to seven-membered cycloalkyl, Het, Hetaryl, -CO-N(CH3)2, -CO-NHCH3, -CO-NH2, -(C1-3-alkylene)-O-(C1-3-alkyl), -O- Het, which is optionally further substituted by one, two or three substituents X, whereby each X is selected from the group consisting of halogen, oxo, -O-C1-4-alkyl, -C1-4-haloalkyl, -O-(C1-4-alkylene)- Het, Het, -NH2, whereby each substituent X is optionally further substituted by one, two or three substituents of a group selected from oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl, and the pharmaceutically acceptable salts of the aforementioned compounds. 
OH, okso, -CN, halogen, -C1-6-alkil, -O-C1-6-alkil, -C1-6-haloalkil, tročlani do sedam-člani cikloalkil, Het, Hetaril, -CO-N(CH3)2, -CO-NHCH3, -CO-NH2, -(C1-3-alkilen)-O-(C1-3-alkil), O-Het, koji je opcionalno dalje supstituiran s jednim, dva ili tri supstituenta X, pri čemu je svaki X odabran iz skupine koja se sastoji od sljedećih: halogen, okso, -C1-4-alkil, -O-C1-4-alkil, -C1-4-haloalkil, -O-(C1-4-alkilen)-Het, Het, -NH2, pri čemu je supstituent X opcionalno dalje supstituiran s jednim, dva ili tri supstituenta iz skupine odabrane od okso, metila, etila, n-propila, izopropila, n-butila, izobutila i tert-butila, i farmaceutski prihvatljive soli od gore spomenutih spojeva.
The compound of formula 1b or of formula 1b' according to claim 1, which is selected from the group consisting of and and the pharmaceutically acceptable salts of the aforementioned compounds. 
Spoj formule 1c ili formule 1c’ prema patentnom zahtjevu 17, naznačen time, da je odabran iz skupine koja se sastoji od sljedećih: i farmaceutski prihvatljive soli od gore spomenutih spojeva.
The compound of claim 8 for use for the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, adult respiratory distress syndrome, bronchitis, allergic dermatitis, contact dermatitis, idiopathic thrombocytopenic purpura, rheumatoid arthritis, lupus erythematodes, lupus nephritis and allergic rhinoconjunctivitis. 
Spoj za uporabu u liječenju bolesti u skladu s patentnim zahtjevom 30, naznačen time, da je bolest odabrana iz skupine koja se sastoji od astme, KOPB-a, alergijskog rinitisa, sindroma opasnog respiratornog poremećaja kod odraslih, bronhitisa, alergijskog dermatitisa, kontaktnog dermatitisa, idiopatske trombocitopenijske purpure, reumatoidnog artritisa, lupus eritematode, lupus nefritisa i alergijskog rinokonjunktivitisa.
A composition comprising the bacterium deposited under accession number NCIMB 42380 or a bacterium that has a 16s rRNA sequence that is at least 98% identical to SEQ ID NO:1, for use in a method of treating or preventing neutrophilic asthma. 
Sastav koji obuhvaća održivu bakteriju koja je deponirana pod pristupnim brojem NCIMB 42380 ili održivu bakteriju koja ima 16s rRNK sekvencu koja je najmanje 98% identična sa SEQ ID NO:1, za upotrebu u postupku liječenja ili prevencije raka.
The composition for use according to any preceding claim, for use in a method of reducing IL-17 production or reducing Th17 cell differentiation in the treatment or prevention of neutrophilic asthma. 
Sastav za upotrebu prema bilo kojem prethodnom zahtjevu, pri čemu je sastav za upotrebu u postupku smanjenja proizvodnje IL-17 ili smanjenja diferencijacije Th17 stanica u liječenju ili prevenciji raka.
The composition for use according to any preceding claim, for use in a patient with elevated IL-17 levels or Thl7 cells. 
Sastav za upotrebu prema bilo kojem prethodnom zahtjevu, pri čemu je sastav za upotrebu kod pacijenta s povišenim IL-17 razinama ili Th17 stanicama.
The composition for use according to any preceding claim, wherein the bacterium has a 16s rRNA sequence that is at least 99%, 99.5% or 99.9% identical to SEQ ID NO:1. 
Sastav za upotrebu prema bilo kojem od zahtjeva 1-4, pri čemu bakterija ima 16s rRNK sekvencu koja je najmanje 99%, 99.5% ili 99.9% identična sa SEQ ID NO:1.
The isolated antibody of any of claims 1-7, or the isolated antibody or fragment of claim 8, for use in treating or preventing, or reducing the symptoms of, a neurodegenerative disease that involves pathological aggregation of tau within the brain. 
Izolirano antitijelo prema bilo kojem od zahtjeva 1-4 za upotrebu u liječenju ili prevenciji, ili smanjenju simptoma, neurodegenerativne bolesti koja uključuje patološko skupljanje tau u mozgu. Izolirano antitijelo za upotrebu prema zahtjevu 11, gdje je neurodegenerativna bolest Alzheimerova bolest.
A process comprising converting a compound of formula (I) into a compound of formula (II) by reaction with a monometal organolithium reagent in a suitable solvent, wherein P and P' are independently protective groups, 
Postupak, naznačen time što se sastoji u prevođenju spoja formule (I) u spoj formule (II) reakcijom s monometalnim organolitijskim reagensom u pogodnom otapalu, gdje su P i P’ neovisno zaštitne skupine,
and R2 taken together form a 5- or 6-membered (hetero)cycloalkyl group and X is halogen. 
i R2 uzeti zajedno tvore 5- ili 6-eročlanu (hetero)cikloalkilnu skupinu i X je halogen.
The process according to any one of claims 1-5 further comprising converting the compound of formula (II) into a compound of formula (III) by either a one-step or two-step reaction with a chlorinating reagent, wherein R1, R2, R3, P and P' have the meaning as defined in claim 1. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što dodatno uključuje prevođenje spoja formule (II) u spoj formule (III) bilo reakcijom jednom koraku ili u dva koraka s klorirajućim reagensom, gdje R1, R2, R3, P i P’ imaju značenje kao što je definirano u patentnom zahtjevu 1.
The process according to claim 6, wherein the chlorinating reagent is selected from the group consisting of LiCl, KCl, NaCl, NH4Cl, HCl, AlCl3 in concentrated HCl, PPh3/CCl4, PPh3/NCS, SOCl2 and PCl3/PCl5. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što se klorirajući reagens bira iz skupine koju čine LiCl, KCl, NaCl, NH4Cl, HCl, AlCl3 u koncentriranom HCl, PPh3/CCl4, PPh3/NCS, SOCl2 i PCl3/PCl5.
removal of the P protective group and 
uklanjanjem zaštitne skupine P i
reaction with a compound of formula (V) in the presence of a coupling reagent followed by 
reakcijom sa spojem formule (V) u prisutnosti konjugacijskog reagensa, za čim slijedi
elimination of the P' protective group, wherein R1, R2, R3, P and P' have the meaning defined in claim 1, P" is independently a protective group and X1, X2, X3 are independently C or N. 
eliminacija zaštitne skupine P’, gdje R1, R2, R3, P i P’ imaju značenja definirana u patentnom zahtjevu 1, P” je neovisno zaštitna skupina i, X2, X3 su neovisno C ili N.
The process according to claim 9, wherein the coupling reagent is selected from the group consisting of BOP, DCC, DIC, EDC, HATU, TBTU and T3P. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što se konjugacijski reagens bira iz skupine koju čine BOP, DCC, DIC, EDC, HATU, TBTU i T3P.
at least one oil; and at least one surfactant, wherein the active agent is an antibiotic; 
najmanje jedno ulje; i najmanje jedan surfaktant, pri čemu aktivno sredstvo je antibiotik;
is selected from the group consisting of a beta-lactam, penicillin, cephalosporin, aminoglycoside, quinolones, sulphonamides, tetracyclines and macrocyclic antibiotic; and/or 
odabrano iz skupine koja se sastoji od beta-laktama, penicilina, cefalosporina, aminoglikozida, kinolona, sulfonamida, tetraciklina i makrocikličkog antibiotika; i/ili
is selected from the group consisting of cloxacillin, tylosin, cephapirin, and combinations thereof. 
odabrano iz skupine koja se sastoji od kloksacilina, tilozina, cefapirina i njihovih kombinacija.
an antibiotic and a non-steroidal anti-inflammatory drug. 
antibiotika i nesteroidnog protuupalnog lijeka.
a non-ionic surfactant and is selected from the group consisting of sorbitan esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene castor oil derivatives, polyoxyethylene stearates, polyethylene oxide monooleate and combinations thereof. 
neionski surfaktant i odabran je iz skupine koju čine sorbitan esteri, polioksietilen sorbitan esteri masnih kiselina, derivati polioksietilen ricinusovog ulja, polioksietilen stearati, polietilen oksid monooleat i njihove kombinacije.
The composition as claimed in any one of claims 1 to 11 wherein the oil is selected from the group consisting of medium chain triglycerides, light liquid paraffin, ethyl oleate and sesame oil. 
Pripravak prema bilo kojem od patentnih zahtjeva 1 do 11 naznačen time što je ulje odabrano iz skupine koja se sastoji od triglicerida srednjeg lanca, lakog tekućeg parafina, etil oleata i sezamovog ulja.
The composition as claimed in any one of claims 1 to 13 wherein the composition has a viscosity below 300 mPas at a shear rate of 100 1/s and temperature of 20°C, or a viscosity below 150 mPas at a shear rate of 100 1/s and temperature of 20°C. 
Pripravak prema bilo kojem od patentnih zahtjeva 1 do 13 naznačen time što pripravak ima viskoznost ispod 300 mPas pri brzini smicanja od 100 1/s i temperaturi od 20°C, ili viskoznost ispod 150 mPas pri brzini smicanja od 100 1/s i temperaturi od 20°C.
mixing the oil and surfactant in a container to form a homogenous oil mixture; 
miješanje ulja i surfaktanta u spremniku da se dobije homogena smjesa ulja;
subsequently adding the hydrophobic colloidal silica to the oil mixture. 
naknadno dodavanje hidrofobne koloidne silike u smjesu ulja.
The dietary composition of claim 11 comprising no more than 0.1 g phenylalanine per 100 g total protein. 
Prehrambeni pripravak sukladno zahtjevu 11 naznačen time da sadrži ne više od 0,1 g fenilalanina na 100 g ukupnog proteina.
for wrapping around pipework or a vessel (90), 
za omotavanje cjevovoda ili posude (90),
for making prefabricated parts for equipment insulation, such as insulation (80) shells for valves, flanges and fittings, or 
za izradu montažnih dijelova za izolaciju opreme, poput izolacije (80) kućišta za ventile, prirubnice i spojnice, ili
for thermal and/or acoustic insulation (80) of installations underwater, underground or underneath screed or concrete. 
za toplinsku i/ili zvučnu izolaciju (80) podvodnih, podzemnih instalacija ili ispod estriha ili betona.
A composition comprising a mixture containing fluorinated hydrocarbons, the mixture comprising ≥ 99.5 wt.-% of a total of difluoromethane (R32), pentafluoroethane (R125) and 1,1,1,2-tetrafluoroethane (R134a), and the composition ratio of R32, R125 and R134a in the mixture falls within a triangle having the points A, F and G as vertices in a ternary composition diagram in which the sum of R32, R125 and R134a is 100 wt.-%: 
Sastav koji sadrži mješavinu koja obuhvaća difluormetan (R32), pentafluoretan (R125), i 1,1,1, 2-tetrafluoretan (R134a), pri čemu u ternarnom dijagramu sastava, u kojem zbroj koncentracija (u w.-%) R32, R125 i R134a iznosi 100 w.-%, omjer sastava R32, R125 i R134a sadržan u mješavini pada unutar trokuta koji ima točke A, F i G kao vrhove:
The composition of claim 1 or 2, wherein the mixture consists of R32, R125, and R134a. 
Sastav prema bilo kojem od zahtjeva 1 – 4, naznačen time da se mješavina sastoji od R32, R125, i R134a.
The composition of any of claims 1-6, wherein the mixture has a GWP of ≤ 1500, and the refrigerating capacity of the mixture is ≥ 94% relative to that of R404A. 
Sastav prema bilo kojem od zahtjeva 1 – 5, naznačen time da mješavina ima GWP od ≤ 1500, i kapacitet hlađenja mješavine je ≥ 94% u odnosu na kapacitet hlađenja R404A.
The use of the composition of any of claims 1-10in at least one of refrigerators, freezers, water coolers, ice machines, refrigerating showcases, freezing showcases, freezing and refrigerating units, refrigerating devices for freezing and refrigerating warehouses, chillers (chilling units), turbo refrigerators, and screw refrigerators. 
Sastav prema bilo kojem od zahtjeva 1 – 10, koji se koristi za barem jedan od hladnjaka, zamrzivača, uređaja za hlađenje vode, ledomata, rashladnih vitrina, vitrina za zamrzavanje, jedinica za zamrzavanje i hlađenje, rashladnih uređaja za skladišta za zamrzavanje i hlađenje, rashladni uređaji (jedinice), turbo hladnjaci, i vijčani hladnjak.
The peptide of claim 1 or 2, wherein the peptide 
Peptid patentnog zahtjeva 1 ili 2, nadalje sadrži
one or more moieties covalently linked to the N-terminus of the peptide, wherein the one or more moieties are selected from the group consisting of an acetyl group, a stearyl group, a fatty acid, a cholesterol, a poly-ethylene glycol, a nuclear localization signal, a nuclear export signal, an antibody or antibody fragment thereof, a peptide, a polysaccharide, and a targeting molecule; optionally wherein the peptide comprises an acetyl group covalently linked to its N-terminus; and/or 
jedan ili više dijelova kovalentno vezanih na N-terminalni kraj peptida, pri čemu je jedan ili više dijelova odabrano iz grupe koja se sastoji od acetilne skupine, stearilne skupine, masne kiseline, kolesterola, polietilen glikola, signala nuklearne lokalizacije, nuklearnog izvoznog signala, antitijela ili njegovog fragmenta antitijela, peptida, polisaharida i ciljne molekule; i/ili
A complex or nanoparticle comprising the peptide of any one of claims 1-4; and a cargo molecule, optionally wherein the cargo molecule is 
Kompleksni spoj, koji sadrži peptid bilo kojeg patentnog zahtjeva 1-4 i molekulu tereta. Nanočestica, koja sadrži peptid bilo kojeg patentnog zahtjeva 1-4 i molekulu tereta.
the molar ratio of the cargo molecule to the peptide in the nanoparticle is from about 1:1 to about 1:80, optionally wherein the molar ratio of the cargo molecule to the peptide in the nanoparticle is from about 1:5 to about 1:40; 
Nanočestica prema patentnom zahtjevu 6 ili 7, pri čemu je molarni omjer molekule tereta i peptida u nanočesticama je od oko 1:1 do oko 1:80, pri čemu je molarni omjer molekule tereta i peptida u nanočesticama opcijski od oko 1:5 do oko 1:40;
the pharmaceutically acceptable carrier is a sugar or a protein, optionally wherein the sugar is selected from the group consisting of sucrose, glucose, mannitol, and a combination thereof, and is present in the pharmaceutical composition at a concentration from about 5% to about 20%, optionally wherein the protein is albumin; and/or 
farmaceutski prihvatljiv nosač je šećer ili protein, pri čemu se opcijski odabire šećer iz skupine koja se sastoji od saharoze, glukoze, manitola i njihove kombinacije, a prisutan je u farmaceutskom pripravku u koncentraciji od oko 5 % do oko 20 %; i/ili protein albumin; i/ili je farmaceutski spoj liofiliziran.
A propulsion system for a boat, comprising: 
Pogonski sistem (1) za brod, koji sadrži:
Propulsion system according to claim 10, wherein said rods are rotary and threaded. 
Pogonski sistem prema patentnom zahtjevu 10, gdje su navedene šipke (406) rotacione i sa navojem.
Propulsion system according to claim 11 wherein said rods are fixed to said upper flange and said lower flange by semi-rigid inserts. 
Pogonski sistem prema patentnom zahtjevu 11 gdje su navedene šipke pričvršćene na prirubnice pomoću polukrutih umetaka (408).
Boat equipped with a propulsion system according to claim 1 . 
Brod opremljen pogonskim sistemom prema jednom od patentnih zahtjeva 1 do 14.
A pharmaceutical composition comprising at least one Omega-3 fatty acid ester and at least one surface active agent; wherein said at least one Omega-3 fatty acid ester comprises at least 40% (wt/wt) of the composition, wherein said at least one surface active agent comprises a combination of at least one polysorbate and at least one poloxamer, said at least one polysorbate comprises from 15% wt/wt to 31% wt/wt, wherein said at least one poloxamer comprises from 0.5% wt/wt to 5% wt/wt of said composition, wherein said at least one poloxamer is poloxamer 237, and wherein said composition is free of Omega-3 free fatty acids. 
Farmaceutski pripravak, naznačen time što sadrži najmanje jedan ester omega-3 masne kiseline i najmanje jedno površinski aktivno sredstvo; gdje navedeni najmanje jedan ester omega-3 masne kiseline čini najmanje 40 % (tež./tež.) pripravka, gdje navedeno najmanje jedno površinski aktivno sredstvo sadrži kombinaciju od najmanje jednog polisorbata i najmanje jednog poloksamera, navedeni najmanje jedan polisorbat čini od 15 % tež./tež. do 31 % tež./tež., gdje navedeni najmanje jedan poloksamer čini od 0,5 % tež./tež. do 5 % tež./tež. navedenog pripravka, gdje je navedeni najmanje jedan poloksamer poloksamer 237, i gdje navedeni pripravak ne sadrži omega-3 masne kiseline.
The pharmaceutical composition according to any one of the preceding claims, wherein said Omega-3 fatty acid ester is DHA ester or EPA ester. 
Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je navedeni ester omega-3 masne kiseline ester DHA ili ester EPA.
The pharmaceutical composition according to claim 15, wherein said composition comprises from 0.01% wt/wt to 5% wt/wt of d-limonene or natural orange oil. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 15, naznačen time što navedeni pripravak sadrži od 0,01 % tež./tež. do 5 % tež./tež. d-limonena ili prirodnog narančinog ulja.
The pharmaceutical composition according to claim 9, wherein the said EPA and DHA ethyl esters combined comprise from 40% (wt/wt) to 95% (wt/wt) of the total omega-3 fatty acid esters in said composition. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 9, naznačen time što navedeni etilni esteri EPA i DHA kombinirani čine od 40 % (tež./tež.) do 95 % (tež./tež.) ukupnih estera omega-3 masnih kiselina u navedenom pripravku.
A gel composition comprising a poorly soluble drug which is aripiprazole or a salt thereof, or 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, water, and a suspending agent, wherein the suspending agent comprises polyvinylpyrrolidone, the poorly soluble drug has a mean primary particle diameter of 0.5 to 30 µm and is contained in a concentration of 200 to 600 mg/mL, and the concentration of polyvinylpyrrolidone is 0.1 to 100 mg/mL. 
Pripravka gela koji sadrži slabo topivi lijek koji je aripiprazol ili njegova sol, ili 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoksi]-1H-kinolin-2-on ili njegova sol, vodu, i sredstvo za suspendiranje, naznačen time što sredstvo za suspendiranje sadrži polietilen glikol i karboksimetil celulozu ili njihovu sol, i pri čemu slabo topivi lijek ima prosječni promjer primarnih čestica od 0.5 do 30 µm i sadržan je u koncentraciji od 200 do 600 mg/mL.
An injectable preparation according to any one of claims 1 to 3, claims 5 to 9 comprising a composition comprising a poorly soluble drug which is aripiprazole or a salt thereof, or 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, water, and a suspending agent, wherein the suspending agent comprises polyvinylpyrrolidone, the poorly soluble drug has a mean primary particle diameter of 1 to 10 µm and is contained in a concentration of 200 to 400 mg/mL, and the concentration of polyvinylpyrrolidone is 0.1 to 100 mg/mL, the composition being in the form of a gel when allowed to stand, and changing to a sol when subjected to an impact, and which is a sustained release preparation being suitable for administration once per month. 
Injekcijski pripravak prema bilo kojem od patentnih zahtjeva 1 do 3, zahtjeva 5 do 12 i 15 koji sadrži pripravak koji obuhvaća: slabo topivi lijek koji je aripiprazol ili njegova sol, ili 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoksi]-1H-kinolin-2-on ili njegova sol, vodu, i sredstvo za suspendiranje, pri čemu sredstvo za suspendiranje sadrži polietilen glikol i karboksimetil celulozu ili njihovu sol, i pri čemu slabo topivi lijek ima prosječni promjer primarnih čestica od 1 do 10 µm i sadržan je u koncentraciji od 200 do 400 mg/mL, pripravak je obliku gela kada se ostavi stajati, te prelazi u koloidnu fazu kada je podvrgnut udarcu, i koji je pripravak s produljenim otpuštanjem i pogodan je za davanje jednom mjesečno.
An injectable preparation according to any one of claims 1 to 3 amd claims 5 to 9 comprising a composition comprising a poorly soluble drug which is aripiprazole or a salt thereof, or 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, water, and a suspending agent, wherein the suspending agent comprises polyvinylpyrrolidone, the poorly soluble drug has a mean primary particle diameter of 4 to 30 µm and is contained in a concentration of 300 to 600 mg/mL, and the concentration of polyvinylpyrrolidone is 0.1 to 100 mg/mL, the composition being in the form of a gel when allowed to stand, and changing to a sol when subjected to an impact, and which is a sustained release preparation being suitable for administration once every two to three months. 
Injekcijski pripravak prema bilo kojem od patentnih zahtjeva 1 do 3, zahtjeva 5 do 12 i 15 koji sadrži pripravak koji obuhvaća slabo topivi lijek koji je aripiprazol ili njegova sol, ili 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoksi]-1H-kinolin-2-on ili njegovu sol, vodu, te sredstvo za suspendiranje, pri čemu sredstvo za suspendiranje sadrži polietilen glikol i karboksimetil celulozu ili njegovu sol, i pri čemu slabo topivi lijek ima prosječni promjer primarnih čestica od 4 do 30 µm i sadržan je u koncentraciji od 300 do 600 mg/mL, pripravak je u obliku gela kada se ostavi stajati, te prelazi u koloidnu fazu kada je podvrgnut udarcu, i koji je pripravak s produljenim otpuštanjem i pogodan je za davanje jednom svaka dva do tri mjeseca.